A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

NCT ID: NCT00385502

Last Updated: 2020-09-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-09-30
• Study Completion Date: 2008-06-30

Brief Summary

Approximately 40 qualified subjects with mild-to-moderate great toenail fungus infection will be treated for 48 weeks with lacquer application to at least one affected great toenail. All subjects will receive treatment with EcoNail™ lacquer.

Detailed Description

This study will use a multi-center, open-label study design in subjects with onychomycosis of at least one great toenail to assess the safety, local tolerability, and efficacy of chronic daily ungual application of EcoNail™. Forty (40) evaluable subjects will apply study drug daily to at least one affected great toenail for 48 weeks. The subjects must comply with all inclusion and exclusion criteria.

Conditions

Onychomycosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

EcoNail™

econazole 5%/SEPA® 18% nail lacquer

Group Type: EXPERIMENTAL

EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)

Intervention Type: DRUG

nail lacquer applied daily for 48 weeks

Interventions

EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)

nail lacquer applied daily for 48 weeks

Intervention Type: DRUG

Other Intervention Names

econazole; SEPA

Eligibility Criteria

Inclusion Criteria

• Subjects who are men and women greater than or equal to 18 years of age and less than or equal to 65 years of age.
• Female subjects who are post-menopausal (amenorrheic for at least 1 year), surgically sterile, have a partner with a vasectomy, or routinely using an acceptable means of contraception (acceptable methods may include hormonal contraceptives, intrauterine device, spermicide and barrier, abstinence and partner/spouse sterility).
• Subjects who have mycologically confirmed distal subungual onychomycosis of at least one or both great toenails ("target toenails"), defined as a positive result by office-based KOH preparation (± Chlorazol B) and by laboratory culture demonstrating one of more of the following organisms: T. rubrum, T. mentagrophytes, T. tonsurans and/or E. floccosum
• Subjects who have target toenail showing 20-65% (+/- 2%) involvement as judged by the clinical investigator.
• Subjects who have target toenail showing great than or equal to 3 mm distal involvement as judged by the clinical investigator.
• Subjects who have target toenail showing great than or equal to 2 mm proximal clear nail at the cuticle.
• Subjects must agree not to apply other nail polish or related products to the affected nails for the duration of the study.
• Subjects must refrain from filing, clipping, or otherwise disturbing the treated nail(s) for the duration of the study [NOTE: Clinic personnel will debride the affected nails during monthly visits. Subjects should not engage in these activities at home during the course of the study.]
• Subjects must have the ability to understand the nature of the study and any hazards of participating in it and the willingness to communicate satisfactorily with the investigator and staff and to participate in, and comply with the requirements of the entire study.
• Subjects must be able to read and sign the study Informed Consent form and comply with the requirements outlined in the informed consent form.

Exclusion Criteria

• Subjects with < 20% or > 65% (+/- 2%) involvement of the target toenail.
• Subjects with great than or equal to 4 mm thickness of the target toenail.
• Subjects with totally dystrophic great toe.
• Subjects with great toenails which show white superficial or proximal subungual onychomycosis, or a "spike" of onychomycosis extending to the cuticle.
• Subjects whose nail cultures grow Candida species as the only pathogen.
• Subjects who have reported treatment with a topical anti-fungal agent for onychomycosis during the four weeks prior to screening for this study.
• Subjects who have been treated with a systemic anti-fungal agent during the three months prior to screening for this study.
• Subjects with any other nail abnormality or dermatological condition, including (but not limited to) psoriasis and lichen planus, that could prevent obtaining a normal-appearing toenail if complete cure was achieved or could otherwise interfere with required study assessments.
• Subjects with a history of organ transplantation, Human Immunodeficiency Virus (HIV) seropositivity or other historical or clinical evidence of an immunocompromised state.
• Subjects with a history of uncontrolled insulin-dependent diabetes mellitus.
• Subjects with a history of diabetic peripheral neuropathy.
• Subjects with a history of clinically significant lower extremity peripheral occlusive vascular disease.
• Subjects with a presence of plantar (moccasin) tinea pedis.
• Subjects with a history of hypersensitivity or allergic reactions on the skin or nails, including reactions to nail polish and/or nail polish remover.
• Subjects known to have an allergy to econazole, ethanol, Eudragit, or SEPA.
• Female subjects who are pregnant or lactating.
• Subjects with clinically relevant abnormal history, physical findings, or laboratory values at the screening assessment that could interfere with the objectives or the safety of the volunteer.
• Subjects who have a condition or abnormality that in the investigator's opinion may interfere with the assessments, conduct of the study, may affect the subject's safety, or is otherwise unsuitable for enrollment.
• Subjects who are currently participating or, within the previous 30 days, have participated in another investigational drug study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abeona Therapeutics, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael H. Silverman, MD

Role: STUDY_DIRECTOR

Biostrategics Consulting, Ltd.

Locations

Tucson, Arizona, United States

New York, New York, United States

Portland, Oregon, United States

Countries

United States

Related Links

http://www.accesspharma.com/index.shtml

Sponsor's website

Other Identifiers

MCHM EC-200

Identifier Type: -

Identifier Source: org_study_id